Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Tamargo

Showing results (51-60 of 184) with videos related to

Pageof 19
Sort By:
Cardiovascular Research|September 19, 2002
Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)Ricardo Caballero, Ignacio Moreno, Teresa González, et al.
British Journal of Pharmacology|May 2, 2003
Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valinesRicardo Caballero, Marc Pourrier, Gernot Schram, et al.
Pharmacology & Therapeutics|February 9, 2007
Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapyJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
Frontiers in Bioscience : a Journal and Virtual Library|November 28, 2006
Genetically engineered mice as a model for studying cardiac arrhythmiasJuan Tamargo, Ricardo Caballero, Lucía Núñez, et al.
Cardiovascular Drugs and Therapy|March 31, 2022
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and GapsJeffrey Triska, Juan Tamargo, Biykem Bozkurt, et al.
Revista Espanola De Cardiologia|January 29, 2008
[The HERACLES Cardiovascular Network]Jaume Marrugat, José R López-López, Magdalena Heras, et al.
Cardiovascular & Hematological Disorders Drug Targets|June 19, 2009
Investigational positive inotropic agents for acute heart failureJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
British Journal of Pharmacology|June 28, 2005
Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channelsRicardo Gómez, Lucía Núñez, Ricardo Caballero, et al.
Revista Espanola De Cardiologia (English Ed.)|January 28, 2020
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?José R González-Juanatey, Juan Tamargo, Ferran Torres, et al.
Cardiovascular Research|November 13, 2004
Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrationsRicardo Caballero, Ricardo Gómez, Lucía Núñez, et al.
Pageof 19

Showing results (51-60 of 184) with videos related to

Sort By:
Pageof 19
Cardiovascular Research|September 19, 2002
Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)Ricardo Caballero, Ignacio Moreno, Teresa González, et al.
British Journal of Pharmacology|May 2, 2003
Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valinesRicardo Caballero, Marc Pourrier, Gernot Schram, et al.
Pharmacology & Therapeutics|February 9, 2007
Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapyJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
Frontiers in Bioscience : a Journal and Virtual Library|November 28, 2006
Genetically engineered mice as a model for studying cardiac arrhythmiasJuan Tamargo, Ricardo Caballero, Lucía Núñez, et al.
Cardiovascular Drugs and Therapy|March 31, 2022
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and GapsJeffrey Triska, Juan Tamargo, Biykem Bozkurt, et al.
Revista Espanola De Cardiologia|January 29, 2008
[The HERACLES Cardiovascular Network]Jaume Marrugat, José R López-López, Magdalena Heras, et al.
Cardiovascular & Hematological Disorders Drug Targets|June 19, 2009
Investigational positive inotropic agents for acute heart failureJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
British Journal of Pharmacology|June 28, 2005
Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channelsRicardo Gómez, Lucía Núñez, Ricardo Caballero, et al.
Revista Espanola De Cardiologia (English Ed.)|January 28, 2020
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?José R González-Juanatey, Juan Tamargo, Ferran Torres, et al.
Cardiovascular Research|November 13, 2004
Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrationsRicardo Caballero, Ricardo Gómez, Lucía Núñez, et al.
Pageof 19